258 participants
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-05-22
- Start Date:
- 2026-05-27
- Completion:
- 2027-05-25
Conditions
- Multiple Myeloma (MM)
Interventions
- DRUG
No Results Yet